Everything below concerns GHRH analogue. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-14. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
Interestingly, relocalization of eIF4E from the nucleus to the cytoplasm correlated with clinical remissions indicative of the relevance of its nuclear activities to disease progression. Subsequent ribavirin trials in AML in combination with antileukemic drugs again showed objective clinical responses including remissions and molecular targeting of eIF4E. Clinical responses correlated with reduced nuclear eIF4E and clinical relapse with re-emergence of eIF4E nuclear eIF4E and its RNA export activity in these AML studies. Other studies used ribavirin in combination showed similar promising results in head and neck cancer. Ribavirin impairs all of the activities of eIF4E examined to date (splicing, capping, RNA export and translation). Thus, eIF4E has been successfully therapeutically targetable in humans; however drug resistance to ribavirin is an emergent problem to long term disease control. eIF4E has also been targeted by antisense oligonucleotides which were very potent in mouse models of prostate cancer, but in monotherapy trials in humans did not provide clinical benefit likely due to the inefficiency of reducing eIF4E levels in humans compared to mice. Recent improvements in nanoparticle delivery may improve this strategy. There is also an allosteric inhibitor of eIF4E which binds between the cap-binding site and the dorsal surface that is used experimentally.
Eosin is also used as a red dye in inks; however, the molecule, especially that of eosin Y, tends to degrade over time, leaving behind its bromine atoms, hence causing paint incorporating such a dye to obtain a darker brown tinge over time. A notable user of eosin dye was the Post-Impressionist painter Van Gogh.
Former Soviet Union leader Mikhail Gorbachev starred in a 1998 Pizza Hut commercial with his granddaughter Anastasia Virganskaya to raise money for the Perestroyka Archives. The ad "obviously exploited the shock value of having a former world leader appear... [and] played on the fact that Gorbachev was far more popular outside Russia than inside it". It was filmed on a multi-million budget with a cinematic quality, including mounting cameras on the Kremlin and shutting down Red Square to get the establishing shots of the square, and dialogue entirely in Russian with English subtitles, to show Pizza Hut as a global brand compared to its American rivals. More recently, Pizza Hut has had various celebrity spokespeople, including Jessica Simpson, the Muppets, Damon Hill, and Murray Walker. In 2000, Pizza Hut paid for their logo to appear on a Russian Proton rocket, which launched the Russian Zvezda module.
== Genetic engineering == The origins of biotechnology culminated with the birth of genetic engineering. There were two key events that have come to be seen as scientific breakthroughs beginning the era that would unite genetics with biotechnology. One was the 1953 discovery of the structure of DNA, by Watson and Crick, and the other was the 1973 discovery by Cohen and Boyer of a recombinant DNA technique by which a section of DNA was cut from the plasmid of an E. coli bacterium and transferred into the DNA of another. This approach could, in principle, enable bacteria to adopt the genes and produce proteins of other organisms, including humans. Popularly referred to as "genetic engineering," it came to be defined as the basis of new biotechnology. Genetic engineering proved to be a topic that thrust biotechnology into the public scene, and the interaction between scientists, politicians, and the public defined the work that was accomplished in this area. Technical developments during this time were revolutionary and at times frightening. In December 1967, the first heart transplant by Christiaan Barnard reminded the public that the physical identity of a person was becoming increasingly problematic. While poetic imagination had always seen the heart at the center of the soul, now there was the prospect of individuals being defined by other people's hearts. During the same month, Arthur Kornberg announced that he had managed to biochemically replicate a viral gene. "Life had been synthesized," said the head of the National Institutes of Health.
Sources: en.wikipedia.org
== Side effects == The main side effects of relugolix for uterine fibroids include abnormal uterine bleeding (24.6–48.6% vs. 6.3% for placebo), hot flashes (42.8–45.5% vs. 0% for placebo), heavy menstrual bleeding (12.1–49.3% vs. 9.4% for placebo), headache (12.3–15.2%), and excessive sweating (9.4–15.2% vs. 0% for placebo). In addition, decreased bone mineral density occurs with relugolix (21.7% decrease by week 12, 24.4% decrease by week 24).
==== Cannabinoids ==== According to a study published in the August 15, 2004 issue of the journal Cancer Research, cannabinoids, the active ingredients in marijuana, restrict the sprouting of blood vessels to gliomas (brain tumors) implanted under the skin of mice, by inhibiting the expression of genes needed for the production of vascular endothelial growth factor (VEGF).
== External links == Austrian Centre of Industrial Biotechnology official website The Centre of Excellence for Biocatalysis - CoEBio3 The University of Exeter - Biocatalysis Centre Center for Biocatalysis and Bioprocessing - The University of Iowa TU Delft - Biocatalysis & Organic Chemistry (BOC) KTH Stockholm - Biocatalysis Research Group Institute of Technical Biocatalysis at the Hamburg University of Technology (TUHH) Biocascades Project
=== Environmental contaminants === Since American kestrels are carnivores, toxic chemical runoff ingested by their prey can concentrate at high levels in their blood. Wild kestrels are subject to immunomodulation, or an altered immune response, to polybrominated diphenyl ethers (PBDEs), a group of industrial flame retardants that may leach from factories into the environment. When PBDEs accumulate in body tissues of kestrels, the T-cell mediated immune response decreases in efficiency. As a result, kestrels that ingest PBDEs may not respond sufficiently to viruses or other invading microorganisms. In addition, certain PBDEs may suppress the growth and development of the spleen and bursa in American kestrels. While PBDEs can affect immune response and suppress growth of certain organs, they can also affect the thyroid system of American Kestrels. Exposure to PBDEs in vivo can alter the thyroid system and retinol concentrations in kestrels. This leads to oxidative stress, lipid peroxidation, and changes in glutathione metabolism. These systems are important in early development, growth, regulation of metabolism, thermoregulation, and reproduction. Oxidative stress is also known to contribute to cancers and neurological diseases. Exposure to polychlorinated biphenyls (PCBs) might also affect American Kestrel reproduction. It was found that PCBs affect the function of carotenoids in kestrels. This led to changes in coloration, especially during breeding season for adults. PCB-exposed males where duller and contributed less to egg incubation than unexposed males.
APEKTx1 is a highly selective blocker of the voltage-gated potassium channel Kv1.1 with no effect on other tested potassium channels (Kv1.2, Kv1.3, Kv1.4, Kv1.5, Kv1.6, Shaker IR, Kv2.1, Kv3.1, Kv4.2 and Kv4.3). APEKTx1 selectively blocks Kv1.1 channels with an IC50 value of 0.9 nM, which makes it between a 700 to 3000 times more potent inhibitor than the two known sea anemone peptides targeted against Kv channels (kalicludines and SHTX II). APEKTx1 is thought to interact with Kv1.1 through the aliphatic residue alanine (A352), an acidic residue glutamate (E353), and an aromatic residue tyrosine (Y379), as a mutation in these sites causes a loss in affinity of the toxin for Kv1.1. These residues are located in the H5-loop between the S5 and S6 domains and are part of the channel’s pore. In addition, APEKTx1 acts as a potent trypsin inhibitor (Kd= 124 nM), probably a competitive one. However, trypsin inhibition is more potent (as it has a higher affinity) in BPTI, which can be explained by the presence of Phe13 and Pro19 in APEKTx1, causing an unfavorable interaction.
Sources: en.wikipedia.org
== Oxygen-17 == Oxygen-17 (17O) is the rarest of the three stable isotopes of oxygen with a low isotopic abundance of about 0.038% = 380 ppm in terrestrial water and air. Naturally 17O is primarily made by burning hydrogen into helium in the CNO cycle, making it a common isotope in the hydrogen burning zones of stars. As the only stable isotope of oxygen possessing a nuclear spin (+5⁄2) and a favorable characteristic of field-independent relaxation in liquid water, through extreme motional narrowing.17O enables NMR studies tracing oxidative metabolic pathways (i.e. conversion of 17O2 gas to metabolically produced H217O water by oxidative phosphorylation in mitochondria) at high magnetic fields. This is a necessary requirement to overcome the low SNR from low abundance, low gyromagnetic ratio and fast quadrupolar transversal relaxation in contrast to proton/hydrogen, which is the most commonly used nucleus in magnetic resonance. Water used as nuclear reactor coolant is subjected to intense neutron flux. Natural water starts out with 0.038% of 17O; heavy water starts out incidentally enriched to about 0.055% in that isotopes. Further, the neutron flux slowly converts 16O in the cooling water to 17O by neutron capture, increasing its concentration. The neutron flux slowly converts 17O (with much greater cross section) in the cooling water to carbon-14, an undesirable product that can escape to the environment:
== History == In June 2000, the European Commission formally approved the launching of Lantus by Sanofi-Aventis Germany in the European Union. The admission was prolonged on 9 June 2005. A three-fold more concentrated formulation, brand name Toujeo, was introduced after FDA approval in 2015.
==== South Ossetian attacks and Georgian response ==== The commission said that a government "is generally not prevented" to use armed force against opposing side in internal conflicts, such as rebels or violent secessionists. However, the report said that Georgia had a non-use of force commitment under the international legal documents, such as the 1992 Sochi Agreement and 1996 Memorandum on Measures to Provide Security and Strengthen Mutual Trust between the Sides in the Georgian-South Ossetian Conflict. The commission said that the South Ossetian attacks on Georgian villages (Zemo Nikozi, Kvemo Nikozi, Avnevi, Nuli, Ergneti, Eredvi and Zemo Prisi) equaled to an "attack by the armed forces of a State on the territory of another State" similar to the situations described in Art. 3(a) of UN Resolution 3314. Since the South Ossetian attacks mainly targeted Georgian peacekeepers and Georgian police, this was "an attack by the armed forces of South Ossetia on the land forces of Georgia". The commission found out that several residents of the assaulted villages became casualties in "the acts preceding the outbreak of the hostilities" and "From 6 August on, continuous heavy fighting took place." The commission could not prove that Russian peacekeepers took part in the attacks on Georgian villages, but noted that "Such attacks were rather initiated by the South Ossetian militia." The commission also said "South Ossetia violated the prohibition of the use of force" as long as South Ossetia had attacked the Georgian villages.
Validation: Ensuring that the device meets the needs and requirements of its intended users and the intended use environment. Verification: Ensuring that the device meets its specified design requirements ISO 9001:2015 (Quality management systems requirements) makes the following distinction between the two activities, when describing design and development controls:
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.